Open House Discount Contracts 2024 11

Deadline: 31 Oct 2026

Germany

Ref. No.: 8612553

EMD:Ref Document

Bid Value: Ref Document

271 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 8570586

EMD:Ref Document

Bid Value: Ref Document

332 Days Left

Pharmaceutical Discount Agreements From 1 November 2024 For Various Active Ingredients As Part Of An Open House Procedure

Deadline: 01 Sep 2026

Germany

Ref. No.: 8564108

EMD:Ref Document

Bid Value: Ref Document

211 Days Left

Open House Original Rebate Agreements 2024 09 Nintedanib Finished Medicinal Product Name Ofev R

Deadline: 31 Oct 2026

Germany

Ref. No.: 8552170

EMD:Ref Document

Bid Value: Ref Document

271 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 8542116

EMD:Ref Document

Bid Value: Ref Document

332 Days Left

The First Non Clogging Continuous Flow Reactor Technology

Deadline: 28 Feb 2026

France

Ref. No.: 8503739

EMD:Ref Document

Bid Value: Ref Document

26 Days Left

Conclusion Of A Non Exclusive Drug Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V By Means Of An Open House Model For The Active Ingredient Glyceryl Trinitrate Atc Code According To Who C01Da02

Deadline: 31 Oct 2026

Germany

Ref. No.: 8314020

EMD:Ref Document

Bid Value: Ref Document

271 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bosutinib

Deadline: 10 May 2026

Germany

Ref. No.: 8312368

EMD:Ref Document

Bid Value: Ref Document

97 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Pomalidomide

Deadline: 10 May 2026

Germany

Ref. No.: 8309306

EMD:Ref Document

Bid Value: Ref Document

97 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredients Mentioned With The Possibility Of Conclusion Within The Framework Of The So Called Open House Procedure

Deadline: 31 Dec 2026

Germany

Ref. No.: 8307985

EMD:Ref Document

Bid Value: Ref Document

332 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Brinzolamide Brimonidine Atr

Deadline: 10 May 2026

Germany

Ref. No.: 8307469

EMD:Ref Document

Bid Value: Ref Document

97 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Omalizumab

Deadline: 10 Aug 2026

Germany

Ref. No.: 8305975

EMD:Ref Document

Bid Value: Ref Document

189 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Pomalidomide

Deadline: 10 May 2026

Germany

Ref. No.: 8305884

EMD:Ref Document

Bid Value: Ref Document

97 Days Left

Conclusion Of Non Exclusive Discount Agreements Pursuant To Section 130 A Paragraph 8 Sgb V With The Active Ingredient Bosutinib

Deadline: 10 May 2026

Germany

Ref. No.: 8305728

EMD:Ref Document

Bid Value: Ref Document

97 Days Left

Conclusion Of A Non Exclusive Discount Agreement Pursuant To Section 130A Para 8 Sgb V For The Active Ingredient Omalizumab

Deadline: 10 Aug 2026

Germany

Ref. No.: 8294730

EMD:Ref Document

Bid Value: Ref Document

189 Days Left

Discover Tenders by Miscellaneous Pharmaceuticals Sector

Filter Your Search

Tenders by Countries

Browse Popular Sectors

Projects by Regions

Funding Agency

Support

CONTACT DETAILS

Discover Tenders by Miscellaneous Pharmaceuticals Sector

Filter Your Search

FREE Trial plan for all new users!